Intratumoral therapies and in-situ vaccination for melanoma

References

• Whiteside T. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904–9. doi:https://doi.org/10.1038/onc.2008.271.
   PubMed Web of Science ®Google Scholar
• Engelhardt JJ, Boldajipour B, Beemiller P, Pandurangi P, Sorensen C, Werb Z, Egeblad M, Krummel M. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell. 2012;21(3):402–17. doi:https://doi.org/10.1016/j.ccr.2012.01.008.
   PubMed Web of Science ®Google Scholar
• Spranger S, Sivan A, Corrales L, Gajewski TF. Tumor and host factors controlling antitumor immunity and efficacy of cancer immunotherapy. Adv Immunol. 2016;130:75–93.
   PubMed Web of Science ®Google Scholar
• Broz ML, Binnewies M, Boldajipour B, Nelson A, Pollack J, Erle D, Barczak A, Rosenblum M, Daud A, Barber D, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26(5):638–52. doi:https://doi.org/10.1016/j.ccell.2014.09.007.
   PubMed Web of Science ®Google Scholar
• Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31(5):711–723.e4. doi:https://doi.org/10.1016/j.ccell.2017.04.003.
   PubMed Web of Science ®Google Scholar
• Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018;24(8):1178–91. doi:https://doi.org/10.1038/s41591-018-0085-8.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715–27. doi:https://doi.org/10.1038/nri1936.
   PubMed Web of Science ®Google Scholar
• Daud AI, Loo K, Pauli ML, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126(9):3447–52.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50. doi:https://doi.org/10.1038/s41591-018-0014-x.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44(3):698–711. doi:https://doi.org/10.1016/j.immuni.2016.02.025.
   PubMed Web of Science ®Google Scholar
• Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. Published online 2016 Aug 15;126(9):3447–52. doi:https://doi.org/10.1172/JCI87324.
   PubMed Web of Science ®Google Scholar
• Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–55. doi:https://doi.org/10.1038/s41586-019-1922-8.
   PubMed Web of Science ®Google Scholar
• Neyt K, Perros F, GeurtsvanKessel CH, Hammad H, Lambrecht BN. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol. 2012;33(6):297–305. doi:https://doi.org/10.1016/j.it.2012.04.006.
   PubMed Web of Science ®Google Scholar
• Coppola D, Mulé JJ. Ectopic lymph nodes within human solid tumors. J Clin Oncol. 2008;26(27):4369–70. doi:https://doi.org/10.1200/JCO.2008.17.6149.
   PubMed Web of Science ®Google Scholar
• Liu H, Weber A, Morse J, Kodumudi K, Scott E, Mullinax J, Sarnaik AA, Pilon-Thomas S. T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model. PLoS One. 2018;13(4):e0196033. doi:https://doi.org/10.1371/journal.pone.0196033.
   PubMed Web of Science ®Google Scholar
• Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res. 2008;18(6):405–11. doi:https://doi.org/10.1097/CMR.0b013e32831328c7.
   PubMed Web of Science ®Google Scholar
• Thompson JF, Agarwala SS, Smithers BM, Ross MI, Scoggins CR, Coventry BJ, Neuhaus SJ, Minor DR, Singer JM, Wachter EA, et al. Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol. 2015;22(7):2135–42. doi:https://doi.org/10.1245/s10434-014-4169-5.
   PubMed Web of Science ®Google Scholar
• Campana L, Valpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, Chiarion-Sileni V, Rossi CR. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg. Published online 2012;99(6):821–30. doi:https://doi.org/10.1002/bjs.8749.
   PubMed Web of Science ®Google Scholar
• Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J, Mir LM. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer. 1993;72(12):3694–700. doi:https://doi.org/10.1002/1097-0142(19931215)72:12<3694::AID-CNCR2820721222>3.0.CO;2-2.
   PubMed Web of Science ®Google Scholar
• Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R. Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol. 1996;132(11):1353–57. doi:https://doi.org/10.1001/archderm.1996.03890350095015.
   PubMedGoogle Scholar
• Rudolf Z, Stabuc B, Cemazar M, Miklavcic D, Vodovnik L, Sersa G. Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol. 1995;29:229–35.
   Google Scholar
• Serša G, Štabuc B, Čemažar M, Miklavčič D, Rudolf Z. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res. 2000;6:863–67.
   PubMed Web of Science ®Google Scholar
• Kunte C, Letulé V, Gehl J, Dahlstroem K, Curatolo P, Rotunno R, Muir T, Occhini A, Bertino G, Powell B, et al. Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by inspect. Br J Dermatol. 2017;176(6):1475–85. doi:https://doi.org/10.1111/bjd.15340.
   PubMed Web of Science ®Google Scholar
• Liu BL, Robinson M, Han Z-Q, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292–303. doi:https://doi.org/10.1038/sj.gt.3301885.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy. 2015;7(6):611–19. doi:https://doi.org/10.2217/imt.15.35.
   PubMed Web of Science ®Google Scholar
• Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 2016;22(5):1048–54. doi:https://doi.org/10.1158/1078-0432.CCR-15-2667.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6(226):226ra32. doi:https://doi.org/10.1126/scitranslmed.3008095.
   PubMed Web of Science ®Google Scholar
• Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte–macrophage colony-stimulating factor. Molecular Therapy. 2000;2(4):324–29. doi:https://doi.org/10.1006/mthe.2000.0130.
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763–71. doi:https://doi.org/10.1200/JCO.2009.24.3675.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–88. doi:https://doi.org/10.1200/JCO.2014.58.3377.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, Ohrling K, Kaufman HL. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma. J Immunother Cancer. 2019;7(1):7. doi:https://doi.org/10.1186/s40425-019-0623-z.
   PubMed Web of Science ®Google Scholar
• Hofbauer GFL, Baur T, Bonnet M-C, Tartour E, Burg G, Berinstein NL, Dummer R. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Res. 2008;18(2):104–11. doi:https://doi.org/10.1097/CMR.0b013e3282f702cf.
   PubMed Web of Science ®Google Scholar
• Andtbacka R, Curti B, Kaufman H, Daniels GA, Nemunaitis JJ, Spitler LE, Hallmeyer S, Lutzky J, Schultz S, Whitman ED, et al. CALM study: a phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma. J Clin Oncol. 2014;32(15_suppl):3031–3031. doi:https://doi.org/10.1200/jco.2014.32.15_suppl.3031.
   Web of Science ®Google Scholar
• Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658–67. doi:https://doi.org/10.1200/JCO.2017.73.7379.
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–1119.e10. doi:https://doi.org/10.1016/j.cell.2017.08.027.
   PubMed Web of Science ®Google Scholar
• Andtbacka R, Dummer R, Gyorki D, Berger AC, Conry RM, Demidov LV, Chan E, Treichel S, Faries MB, Ross MI, et al. Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL). J Clin Oncol. 2018;36(15_suppl):9508–9508. doi:https://doi.org/10.1200/JCO.2018.36.15_suppl.9508.
   Web of Science ®Google Scholar
• Davar D, Karunamurthy A, Hartman D. Phase II trial of neoadjuvant nivolumab (nivo) and intra-tumoral (IT) CMP-001 in high risk resectable melanoma (MEL): preliminary results. Presented at the: 2019 Annual Meeting of the Society for Immunotherapy of Cancer; 2019 Nov 6–10; National Harbor (MD).
   Google Scholar
• Liu T-C, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol. 2007;4(2):101–17. doi:https://doi.org/10.1038/ncponc0736.
   PubMedGoogle Scholar
• Sun J, Gastman BR, McCahon L, Buchbinder EI, Puzanov I, Nanni M, Lewis JM, Carvajal RD, Singh-Kandah S, Desai AM, et al. Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). Melanoma Manag. 2020;7(2):MMT41. doi:https://doi.org/10.2217/mmt-2020-0005.
   PubMedGoogle Scholar
• Daud A, DeConti R, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J clin oncol. 2008;26(36):5896–903. doi:https://doi.org/10.1200/JCO.2007.15.6794.
   PubMed Web of Science ®Google Scholar
• Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, et al. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020;31(4):532–40.
   PubMed Web of Science ®Google Scholar
• Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A et al. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 Feb 1;31(4):532–40. doi:https://doi.org/10.1016/j.annonc.2019.12.008.
   PubMed Web of Science ®Google Scholar
• Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, Zhang L, Paciorek A, Pierce RH, Le MH, et al. Intratumoral plasmid IL12 electroporation therapy in patients with advanced melanoma induces systemic and intratumoral T-cell responses. Cancer Immunol Res. 2020;8(2):246–54. doi:https://doi.org/10.1158/2326-6066.CIR-19-0359.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Longino NV, Miller NJ, Kulikauskas R, Iyer JG, Ibrani D, Blom A, Byrd DR, Parvathaneni U, Twitty C, et al. Intratumoral delivery of plasmid interleukin-12 via electroporation leads to regression of injected and non-injected tumors in merkel cell carcinoma. Clin Cancer Res. 2020 Feb 1;26(3):598–607. doi:https://doi.org/10.1158/1078-0432.CCR-19-0972.
   Google Scholar
• Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, et al. Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma. Clin Cancer Res. Published online 2020 May 6;26(12):2827–37. doi:https://doi.org/10.1158/1078-0432.CCR-19-2217.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment. Adv Exp Med Biol. 2017;1036:19–31.
   PubMed Web of Science ®Google Scholar
• Daud AI, Wolchok JD, Robert C, Hwu W-J, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34(34):4102–09. doi:https://doi.org/10.1200/JCO.2016.67.2477.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. Published online 2017 June 26;127(8):2930–40. doi:https://doi.org/10.1172/JCI91190.
   PubMed Web of Science ®Google Scholar
• Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity. 2018;49(6):1148–1161.e7. doi:https://doi.org/10.1016/j.immuni.2018.09.024.
   PubMed Web of Science ®Google Scholar
• Weide B, Eigentler TK, Pflugfelder A, Leiter U, Meier F, Bauer J, Schmidt D, Radny P, Pföhler C, Garbe C, et al. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother. 2011;60(4):487–93. doi:https://doi.org/10.1007/s00262-010-0957-3.
   PubMed Web of Science ®Google Scholar
• Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RHI, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, et al. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget. 2016;7(39):64390–99. doi:https://doi.org/10.18632/oncotarget.10453.
   PubMedGoogle Scholar
• Fierlbeck G, d’Hoedt B, Stroebel W, Stutte H, Bogenschütz O, Rassner G. Intralesional therapy of melanoma metastases with recombinant interferon-beta. Hautarzt. 1992;43:16–21.
   PubMed Web of Science ®Google Scholar
• Retsas S, Leslie M, Bottomley D. Intralesional tumour necrosis factor combined with interferon gamma in metastatic melanoma. BMJ. 1989;298(6683):1290–91. doi:https://doi.org/10.1136/bmj.298.6683.1290.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol. 1993;11(10):1969–77. doi:https://doi.org/10.1200/JCO.1993.11.10.1969.
   PubMed Web of Science ®Google Scholar
• Paul E, Muller I, Renner H, Bodeker R-H, Cochran AJ. Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional interferon injection. Melanoma Res. 2003;13(6):611–17. doi:https://doi.org/10.1097/00008390-200312000-00011.
   PubMed Web of Science ®Google Scholar
• Kirkwood J, Milhem M, Zakharia Y. Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of toll-like receptor 9 (TLR9) agonist CMP-001, in combination with pembrolizumab. Presented at the: 2019 Annual Meeting of the Society for Immunotherapy of Cancer; 2019 Nov 6–10; National Harbor (MD).
   Google Scholar
• Diab A, Haymaker C, Bernatchez C, Andtbacka RHI, Shaheen M, Johnson D, Markowitz J, Puzanov I, Murthy R, Johnson DH, et al. Intratumoral (IT) injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): results from a multicenter, phase I/II study. Ann Oncol. 2018;29:viii442. doi:https://doi.org/10.1093/annonc/mdy289.001.
   Web of Science ®Google Scholar
• Samoylenko I, Korotkova OV, Zabotina T, Demidov LV. Intralesional anti-PD1 treatment in patients with metastatic melanoma: the pilot study. JCO. 2018;36(5_suppl):188–188. doi:https://doi.org/10.1200/JCO.2018.36.5_suppl.188.
   PubMed Web of Science ®Google Scholar
• Sagiv-Barfi I, Czerwinski DK, Levy S, Alam IS, Mayer AT, Gambhir SS, Levy R. Eradication of spontaneous malignancy by local immunotherapy. Sci Transl Med. 2018;10:426. doi:https://doi.org/10.1126/scitranslmed.aan4488.
   Web of Science ®Google Scholar
• Corrales L, McWhirter SM, Dubensky TW, Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016;126(7):2404–11. doi:https://doi.org/10.1172/JCI86892.
   PubMed Web of Science ®Google Scholar
• Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11:1018–30.
   PubMed Web of Science ®Google Scholar
• Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, Hudson TE, Vu UT, Francica BJ, Banda T, et al. Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity. Cell Rep. 2018;25(11):3074–3085.e5. doi:https://doi.org/10.1016/j.celrep.2018.11.047.
   PubMed Web of Science ®Google Scholar
• Falahat R, Perez-Villarroel P, Mailloux AW, Zhu G, Pilon-Thomas S, Barber GN, Mulé JJ, et al. STING signaling in melanoma cells shapes antigenicity and can promote antitumor T-cell activity. Cancer Immunol Res. 2019;7(11):1837–48.
   PubMed Web of Science ®Google Scholar
• Ribas A, Milhem M, Hoimes C, Amin A. Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. Presented at the: ASCO Annual Meeting; 2019; Chicago, IL.
   Google Scholar
• Taylor DR, Young K, Korrer MJ. The synergy of TLR and STING in cancer immunity. J Immunol. 2020;204:91.30–91.30.
   Web of Science ®Google Scholar
• Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 2017;5(5):417–24. doi:https://doi.org/10.1158/2326-6066.CIR-16-0325.
   PubMed Web of Science ®Google Scholar